Progress in Neuro-Psychopharmacology & Biological Psychiatry

An International Research and Review Journal

Contents, Author Index and Subject Index

Volume 7

L.
83

Pergamon Press

Oxford • New York • Frankfurt

Editor-in-Chief

C. Radouco-Thomas

Laval University Medical School
Quebec, Canada

Executive Editorial Board

T.A. BAN, *Nashville*
H. BARRY III, *Pittsburgh*
F.E. BLOOM, *San Diego*
D.P. BOBON, *Liège*
M.C. BRAUDE, *Rockville*
A. CARLSSON, *Göteborg*
C.L. CAZZULLO, *Milan*
M. CUENOD, *Zurich*
P. DENIKER, *Paris*
J. ELKES, *Baltimore*
D.X. FREEDMAN, *Chicago*
E. GERSHON, *Bethesda*
J. GLOWINSKI, *Paris*
H. HELMCHEN, *Berlin*
F. HOFFMEISTER, *Wuppertal*
L.E. HOLLISTER, *Palo Alto*
O. HORNYKIEWICZ, *Vienna*
A.G. KARCZMAR, *Chicago*
R.T. KELLEHER, *Boston*
P. KIEHOLZ, *Basle*
H. LAL, *Kingston, USA*
A.A. LEEDS, *Rockville*
H.E. LEHMANN, *Montreal*
G.M. LING, *Vienna*
J. MENDLEWICZ, *Brussels*
P. V. MOROZOV, *Geneva*
S. RADOUCO-THOMAS, *Quebec*
O.J. RAFAELSEN, *Copenhagen*
N. SARTORIUS, *Geneva*
S.H. SNYDER, *Baltimore*
H.M. VAN PRAAG, *New York*

URO-PSYCHO 7-A

Progress in Neuro-Psychopharmacology & Biological Psychiatry

An International Research, Review and News Journal

Editors-in-Chief: C. Radouco-Thomas and F. Garcin
Executive Editor: Denise B.-Lacroix
Laboratories of Neuro-Psychopharmacology/RADA Unit, Laval University Medical School and Foundation for Research on Alcoholism, Pharmacodependence and Psychopharmacology, Quebec, Canada
Mailing Address: *Editorial Office, Progress in Neuro-Psychopharmacology & Biological Psychiatry, Casier postal 277, Sillery, Qué., Canada G1T 2R1.*

Executive Editorial Board

T. A. BAN
Vanderbilt University, Nashville
H. BARRY III
University of Pittsburgh, Pittsburgh
F. E. BLOOM
Salk Institute, San Diego
D. P. BOBON
Université de Liège
M. C. BRAUDE
National Institute on Drug Abuse, Rockville
A. CARLSSON
University of Göteborg, Göteborg
C. L. CAZZULLO
Milan
P. DENIKER
Hôpital Ste-Anne, Paris
J. ELKES
Johns Hopkins University, Baltimore
D. X. FREEDMAN
University of Chicago, Chicago
E. GERSHON
Bethesda, Maryland
J. GLOWINSKI
Collège de France, Paris
H. HELMCHEN
Freie Universität, Berlin
F. HOFFMEISTER
Institute of Pharmacology, Bayer AG, Wuppertal
L. E. HOLLISTER
Veterans Administration Hospital, Palo Alto
O. HORNYKIEWICZ
Institute of Biochemical Pharmacology, Vienna
A. G. KARCZMAR
Loyola University, Chicago
R. T. KELLEHER
Harvard Medical School, Boston
P. KIELHOLZ
University of Basle, Basle
H. LAL
Kingston, USA
A. A. LEEDS
National Institute of Mental Health, Rockville
H. E. LEHMANN
McGill University, Montreal
G. M. LING
United Nations, Narcotic Division, Vienna
J. MENDLEWICZ
Brussels
P. V. MOROZOV
Geneva, Switzerland
S. RADOUCO-THOMAS
Laval University Medical School, Quebec
O. J. RAFAELSEN
Psychochemistry Institute, Copenhagen
N. SARTORIUS
Geneva, Switzerland
S. H. SNYDER
Johns Hopkins University, Baltimore
H. M. VAN PRAAG
Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York

Aims and Scope

Progress in Neuro-Psychopharmacology & Biological Psychiatry (PNP & BP Journal) is an international and multidisciplinary research, review and news journal. One of its main aims is to assure rapid publication of authoritative reviews and research papers dealing with experimental and clinical aspects of neuro-psychopharmacology and biological psychiatry. Another important scope of the journal is to supply pertinent information provided by national and international bodies which contributes to progress in the scientific and professional fields. Finally, the journal intends to foster and encourage communications between members of the community of neuropsychopharmacology and biological psychiatry.

Publishing, Subscription and Advertising Offices: Pergamon Press Ltd., Headington Hill Hall, Oxford OX3 0BW. (Oxford 64881; Telex 83177).
Address for subscription enquiries in North America: Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523, U.S.A.
Published bi-monthly. Annual subscription 1985 (including postage and insurance): for Libraries, Research Establishments and all other multiple-reader institutions — U.S. $180.00. Two years 1985/86 – $342.00.
Specially Reduced Rates to Individuals: In the interest of maximizing the dissemination of the research results published in this important journal we have established a two-tier price structure. Any individual whose institution takes out a library subscription may purchase a second or additional subscription for personal use at a much reduced rate of U.S. $60.00 per annum.
Microform Subscriptions and Back Issues: Back issues of all previously published volumes will be available in the regular editions and on microfilm and microfiche. Current subscriptions are available on microfiche simultaneously with the paper edition and on microfilm on completion of the annual index at the end of the subscription year.

Copyright © 1983 Pergamon Press Ltd.

It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. By submitting a manuscript, the authors agree that the copyright for their article is transferred to the publisher if and when the article is accepted for publication. However, assignment of copyright is not required from authors who work for organizations which do not permit such assignment. The copyright covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproductions, microform or any other reproductions of similar nature and translations. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise without permission in writing from the copyright holder.

U.S. Copyright Law applicable to Users in the U.S.A.

The Article Fee code on the first page of an article in this journal indicates the copyright owner's consent that in the U.S.A. copies may be made for personal or internal use provided the stated fee for copying beyond that permitted by Section 107 or 108 of the United States Copyright Law is paid. The appropriate remittance should be forwarded with a copy of the first page of the article to the Copyright Clearance Center Inc., 21 Congress Street, Salem, MA 01970. If a code does not appear copies of the article may be made without charge, provided permission is obtained from the publisher. The copyright owner's consent does not extend to copying for general distribution, for promotion, for creating new works or for resale. Specific written permission must be obtained from the publisher for such copying.
In case of doubt please contact your nearest Pergamon office.

PERGAMON PRESS

HEADINGTON HILL HALL
OXFORD OX3 0BW, ENGLAND

MAXWELL HOUSE, FAIRVIEW PARK
ELMSFORD, NEW YORK 10523, USA

CONTENTS

Volume 7. No. 1

Editorial advisory board

Organization of the journal

F. Garcin and C. Radouco-Thomas — 1 Editorial note

Critical reviews and theoretical articles

C. T. Dourish — 3 Piribedil: Behavioral, neurochemical and clinical profile of a dopamine agonist

L. R. Hartley — 29 Arousal, temporal and spatial uncertainty and drug effects

Full-length original papers

Experimental laboratory studies

R. C. Arora, R. G. Fessler and H. Y. Meltzer — 39 Effects of lithium carbonate on serotonin uptake in rat blood platelets

L. R. Hedley and M. B. Wallach — 47 Potentiation of apomorphine-induced gnawing in mice

A. Fundaro, M. C. Cassone and L. Molinengo — 57 Action of antidepressants, stimulants and depressants in the transition from a fixed ratio to a fixed interval schedule of reinforcement

T. Suzuki, M. Shimada, T. Yoshii, J. Uesugi and S. Yanaura — 63 Development of physical dependence on and tolerance to morphine in rats treated with morphine-admixed food

E. Forney and W. R. Klemm — 73 Unit activity indicators of a catecholamine role in expression of morphine effects

Clinical studies

D. V. Jeste, S. Zalcman, D. R. Weinberger, N. R. Cutler, L. B. Bigelow, J. E. Kleinman, A. Rogol and R. J. Wyatt — 83 Apomorphine response and subtyping of schizophrenia

B. B. Sethi and S. Dubé — 89 Propranolol in schizophrenia

Short and preliminary paper

N. S. Shah, D. A. Powell and A. B. Shah — 101 Regional localization of (^{14}C) methylphenidate in rabbit brain

News and intercommunications in neuro-psychopharmacology

107 Biological approaches to mental health a WHO newsletter

119 Approches biologiques de la sante mentale nouvelles-OMS

131 Report on past meetings

133 Comments on forthcoming meetings

134 Announcement

i Instructions to contributors

v Editorial policy

VOL. 7 1983

CONTENTS

Volume 7. Nos. 2/3

Editorial advisory board

Organization of the journal

Critical reviews and theoretical articles

A. Rotman — 135 Blood platelets in psychopharmacological research

Full-length original papers

S. K. Rastogi, R. B. Rastogi, R. L. Singhal and Y. D. Lapierre — 153 Behavioral and biochemical alterations following haloperidol treatment and withdrawal: The animal model of tardive dyskinesia reexamined

A. B. Shah, R. M. Poiletman and N. S. Shah — 165 The influence of nisoldipine — A "calcium entry blocker" on drug induced stereotyped behavior in rats

S. L. Peterson, T. C. Napier, G. C. Rigdon and J. H. Pirch — 175 Dissimilar responses of cortical neurons to chronic trazodone or desipramine treatment

P. Simon, R. Chermat and A. J. Puech — 183 Pharmacological evidence of the stimulation of central alpha-adrenergic receptors

M. L. Aizenstein, C. Scavone, M. M. Bernardi and R. Delucia — 187 Comparative biochemical and behavioral effects of fencamfamine and DL-amphetamine in rats

G. Cannizzaro, A. Flugy and P. M. Provenzano — 195 Antidipsogenic action of naloxone under different water deprivation conditions

G. Bendek — 203 Effect of FLA-63, *p*-chlorophenylalanine and pimozide on the metabolism and incorporation of ^{3}H-thymidine in the brain of rat pups

Short and preliminary papers

M. Globus and E. Melamed — 211 Combined administration of direct dopamine receptor agonists and L-dopa does not interfere with utilization of exogenous L-dopa in rat corpus striatum

C. L. Ehlers, J. H. Indik, G. F. Koob and F. E. Bloom — 217 The effect of single and repeated electroconvulsive shock (ECS) on locomotor activity in rats

A. V. Kulik and R. Wilbur — 223 Case report of propranolol (inderal) pharmacotherapy for neuroleptic-induced akathisia and tremor

Special Topic:

Clinical mode of action of antidepressants: New advances

Topic Editor: N. Sitaram

N. Sitaram and S. Gershon — 227 From animals models to clinical testing — Promises and pitfalls

S. Kelwala, D. Jones and N. Sitaram — 229 Monoamine metabolites as predictors of antidepressant response: A critique

C. B. Smith, P. J. Hollingsworth, J. A. Garcia-Sevilla and A. P. Zis — 241 Platelet alpha$_2$ adrenoreceptors are decreased in number after antidepressant therapy

L. J. Siever, T. W. Uhde, D. C. Jimerson, M. S. Kafka, C. R. Lake, S. Targum and D. L. Murphy — 249 Clinical studies of monoamine receptors in the affective disorders and receptor changes with antidepressant treatment

CONTENTS

Volume 7. Nos. 2/3, *continued*

R. M. Post, T. W. Uhde, D. R. Rubinow, J. C. Ballenger and P. W. Gold — 263 Biochemical effects of carbamazepine: Relationship to its mechanisms of action in affective illness

N. Sitaram, D. Jones, S. Kelwala, J. Bell, J. Stevenson and S. Gershon — 273 Pharmacology of the human iris: Development and use of challenge strategies in the study of antidepression response

R. H. Belmaker, B. Lerer, E. Klein, M. Newman and E. Dick — 287 Clinical implications of research on the mechanism of action of lithium

D. S. Janowsky, S. C. Risch and J. C. Gillin — 297 Adrenergic – cholinergic balance and the treatment of affective disorders

B. Lerer and N. Sitaram — 309 Clinical strategies for evaluating ECT mechanisms — Pharmacological, biochemical and psychophysiological approaches

G. Langer, H. Aschauer, G. Koinig, F. Resch and G. Schönbeck — 335 The TSH-response to TRH: A possible predictor of outcome to antidepressant and neuroleptic treatment

G. W. Vogel — 343 Evidence for REM sleep deprivation as the mechanism of action of antidepressant drugs

J. C. Gillin — 351 The sleep therapies of depression

J. M. Davis — 365 Concluding remarks: Mechanisms of antidepressants

J. Claghorn, S. Gershon, B. J. Goldstein, S. Behrnetz, D. F. Bush and B. Huitfeldt — 367 A double-blind evaluation of zimelidine in comparison to placebo and amitriptyline in patients with major depressive disorder

News and intercommunications in neuro-psychopharmacology

383 Past and forthcoming meetings

i Instructions to contributors

v Editorial policy

vi Forthcoming papers

Volume 7. Nos. 4–6

Editorial advisory board

Organization of the journal

387 Editorial note

Academic address

T. L. Sourkes — 389 Pathways of stress in the CNS

Plenary lectures

J. Edmeads — 413 The physiology of pain: A review

I. L. Martin — 421 The benzodiazepines: A critical review

N. H. Sternberger — 427 Why monoclonals?

Symposium I — **Drug receptors**

I. L. Martin — 433 The GABA – benzodiazepine receptor complex

CONTENTS

Volume 7. Nos. 4–6, *continued*

R. K. Mishra	437	Modulation of CNS dopamine receptors by peptides
M. Williams	443	Adenosine receptors in the mammalian central nervous system
R. Quirion and C. B. Pert	451	Properties of the phencyclidine (PCP) receptors
P. D. Hrdina	457	Antidepressant binding: Implications for the mode of action and the biology of depression
Symposium II		**Neurotransmitters and neuropeptides in feeding and drinking**
D. V. Coscina	463	GABA and feeding: Reversal of overeating by central GABA-transaminase inhibition
M. D. Evered	469	Neuropeptides and thirst
J. A. Thornhill and W. S. Saunders	477	Acute stimulation of feeding with repeated injections of morphine sulphate to non-obese and fatty Zucker rats
C. T. Dourish	487	Dopaminergic involvement in the control of drinking behavior: A brief review
S. J. Cooper	495	GABA and endorphin mechanisms in relation to the effects of benzodiazepines on feeding and drinking
Symposium III		**Aggression**
R. E. Adamec and C. I. Stark-Adamec	505	Limbic control of aggression in the cat
R. M. Palmour	513	Genetic models for the study of aggressive behavior
K. A. Miczek	519	Ethological analysis of drug action on aggression and defense
R. R. M. Dent	525	Endocrine correlates of aggression
B. A. Davis, P. H. Yu, A. A. Boulton, J. S. Wormith and D. Addington	529	Correlative relationship between biochemical activity and aggressive behavior
Symposium IV		**Pharmacoendocrine approaches to psychiatric disorders**
S. Lal, N. P. V. Nair, H. Eugenio, J. Thavundayil, E. Lizondo, P. L. Wood, P. Etienne and H. Guyda	537	Neuroendocrine evaluation of CCK-peptides on dopaminergic function in man
J. M. Cleghorn, G. M. Brown, P. J. Brown, R. D. Kaplan and J. Mitton	545	Longitudinal instability of hormone responses in schizophrenia
A. J. Lewy	551	Effects of light on human melatonin production and the human circadian system
E. Grof, G. M. Brown and P. Grof	557	Neuroendocrine strategies in affective disorders
A. P. Zis, R. F. Haskett, A. A. Albala and B. J. Carroll	563	Escape from dexamethasone suppression: Possible role of an impaired inhibitory opioid mechanism
Symposium V		**Drug self-administration**
M. A. Bozarth and R. A. Wise	569	Neural substrates of opiate reinforcement
J. Woods	577	Some thoughts on the relations between animal and human drug-taking
A. G. Phillips, C. L. Broekkamp and H. C. Fibiger	585	Strategies for studying the neurochemical substrates of drug reinforcement in rodents

CONTENTS

Volume 7. Nos. 4–6, *continued*

J. Stewart	591	Conditioned and unconditioned drug effects in relapse to opiate and stimulant drug self-administration
Symposium VI		**Recent advances in anxiety and panic disorders**
D. V. Sheehan	599	The diagnosis and drug treatment of anxiety disorders
R. C. Bowen	605	Differential diagnosis of anxiety disorders
P. H. Yu, R. C. Bowen, B. A. Davis and A. A. Boulton	611	A study of the catabolism of trace amines in mentally disordered individuals with particular reference to agoraphobic patients with panic attacks
D. G. Johnston	617	Assessment of agoraphobia and panic disorder
Round table I		**Pharmacokinetics and pharmacodynamics of benzodiazepines**
S. G. McKenzie	623	Introduction to the pharmacokinetics and pharmacodynamics of benzodiazepines
M. L. Jack, W. A. Colburn, N. M. Spirit, G. Bautz, M. Zanko, W. D. Horst and R. A. O'Brien	629	A pharmacokinetic/pharmacodynamic/receptor binding model to predict the onset and duration of pharmacological activity of the benzodiazepines
H. A. Robertson	637	Evidence for distinct benzodiazepine receptors for anticonvulsant and sedative actions: Implications for the treatment of temporal lobe epilepsy
Y. D. LaPierre	641	Are all benzodiazepines clinically equivalent?
Round table II		**Pain and analgesia**
F. S. LaBella, A. K. Dua and C. Pinsky	647	Newer concepts of analgesia and anesthesia
P. F. Vonvoigtlander, R. A. Lewis, G. L. Neff and H. J. Triezenberg	651	Involvement of biogenic amines with the mechanisms of novel analgesics
P. L. Wood	657	Opioid receptor affinities of kappa agonists, agonist/antagonists and antagonists *in vitro* and *in vivo*
Round table III		**Current trends in benzodiazepines: Are they justified?**
L. A. Riblet, A. S. Eison, M. S. Eison, R. E. Newton, D. P. Taylor and D. L. Temple Jr.	663	Buspirone: An anxioselective alternative for the management of anxiety disorders
G. Chouinard, A. Labonte, R. Fontaine and L. Annable	669	New concepts in benzodiazepine therapy: Rebound anxiety and new indications for the more potent benzodiazepines
Round table IV		**Neuropsychiatric implications of astrocytes**
J. S. Richardson and L. Hertz	675	The effects of antidepressant drugs on adenylyl cyclase linked beta adrenergic binding sites on mouse astrocytes in primary cultures
L. Hertz, A. S. Bender and J. S. Richardson	681	Benzodiazepines and β-adrenergic binding to primary cultures of astrocytes and neurons
P. H. Yu and L. Hertz	687	Type A and B monoamine oxidase in glial cells in long-term culture
A. C. H. Yu, E. Hertz and L. Hertz	691	Effects of barbiturates on energy and intermediary metabolism in cultured astrocytes

VOL. 7 1983

CONTENTS

Volume 7. Nos. 4–6, *continued*

W. Walz, E. Hertz and L. Hertz — 697 Lithium-potassium interaction in acutely treated cortical neurons and astrocytes

Workshop I

G. McKay, J. Geddes, M. J. Cowper and T. S. Gurnsey — 703 Recent advances in the analysis of phenothiazine drugs and their metabolites using high performance liquid chromatography

Workshop II

E. M. Hawes, M. Aravagiri, R. A. Dulos, G. A. Rauw and M. D. Stonkus — 709 Radioimmunoassays for phenothiazine drugs and their major metabolites in plasma

Free communications — **Oral presentations and posters**

M. Arato, Z. Rihmer, C. M. Banki and P. Grof — 715 The relationships of neuroendocrine tests in endogenous depression

L. K. Oyewumi, Y. D. LaPierre, R. Gray, S. Batth and R. Gelfand — 719 Abnormal involuntary movements in patients on long-acting neuroleptics

P. L. Wood, N. P. V. Nair, P. Etienne, S. Lal, S. Gauthier, Y. Robitaille, E. D. Bird, J. Palo, M. Haltia and A. Paetau — 725 Lack of cholinergic deficit in the neocortex in Pick's disease

E. Rotstein, R. K. Mishra, D. P. Singal and D. Barone — 729 Lymphocyte ^{3}H-spiroperidol binding in schizophrenia: Preliminary findings

L. K. Oyewumi, Y. D. LaPierre and P. D Hrdina — 733 Clinical effects of mianserin in endogenous depression and their relationship to drug plasma level

S. Chiu, Y. Wong, Y. P. Wan, P. Chiu and R. K. Mishra — 739 Are the pharmacological effects of L-prolyl-L-leucyl-glycinamide (PLG) mediated through specific receptor mechanisms?

K. Dakshinamurti and C. S. Paulose — 743 Consequences of decreased brain serotonin in the pyridoxine-deficient young rat

T. J. Danielson, G. B. Baker, R. T. Coutts and R. G. Micetich — 747 Some *in vivo* responses to a side chain monofluorinated amphetamine in the rat

P. P. Li, J. J. Warsh and D. D. Godse — 751 Metabolic fate of 3,4-dihydroxyphenylethyleneglycol (DHPG) in mouse brain

P. S. McQuade and P. L. Wood — 755 The effects of β-phenylethylamine on tyramine and dopamine metabolism

M. W. Warenycia and G. M. McKenzie — 761 Immobilization-induced changes in the response of striatal neurons to dexamphetamine

P. L. Wood, P. S. McQuade, P. Etienne, S. Lal and N. P. V. Nair — 765 Differential actions of classical and atypical neuroleptics on mouse nigrostriatal neurons

J. Ramwani and R. K. Mishra — 769 A simple and efficient method for solubilization of the dopamine receptor

J. Seggie and R. Kreema — 773 Chlordiazepoxide normalizes behaviour and adrenal response abnormalities in septal rats in a dose and time dependent fashion

G. B. Baker, R. T. Coutts and D. F. Legatt — 779 Levels of *p*-tyramine in rat brain after chronic administration of MAO-inhibiting antidepressants

H. R. McKim, D. G. Calverley, W. G. Dewhurst and G. B. Baker — 783 Regional concentrations of cerebral amines: Effects of tranylcypromine and phenelzine

CONTENTS

Volume 7. Nos. 4–6, *continued*

C. T. Dourish and S. J. Cooper	787	Pharmacology of β-phenylethylamine-induced seizures in mice
J. Dudley, G. Rauw, E. M. Hawes, D. L. Keegan and K. K. Midha	791	Correlation of fluphenazine plasma levels versus clinical response in patients: A pilot study
L. E. Dyck	797	Release of monoamines from striatal slices by phenelzine and β-phenylethylamine
A. J. Greenshaw, J. Broadbent and A. A. Boulton	801	The effects of β-phenylethylamine and phenylethanolamine on water intake in rats: A temporal analysis
Y. D. LaPierre and L. K. Oyewumi	805	Suriclone: A new anxiolytic drug
A. R. Locock, G. B. Baker, R. G. Micetich and R. T. Coutts	809	Stereoisomeric tetrahydro-β-carbolines differ in their interaction with rat brain benzodiazepine receptors
A. J. Nazarali, G. B. Baker, R. T. Coutts and F. M. Pasutto	813	Amphetamine in rat brain after intraperitoneal injection of N-alkylated analogues
S. R. Philips	817	*In vivo* release of endogenous dopamine from rat caudate putamen and nucleus accumbens by 40 mM potassium chloride
S. H. Roth, B. H. Bland and M. B. MacIver	821	Biphasic actions of pentobarbital on synaptic transmission
J. Seggie, E. Werstiuk, L. Grota and G. M. Brown	827	Chronic lithium treatment and twenty-four hour rhythm of serum prolactin, growth hormone and melatonin in rats
E. S. Werstiuk, P. Grof, E. Rotstein and L. Werner	831	Effects of combined haloperidol – lithium treatment on *in vitro* RBC lithium uptake in patients with affective disorders
S. Turkish and S. J. Cooper	835	Fluid consumption in water-deprived rats after administration of naloxone or quaternary naloxone
L. P. Niles and G. M. Brown	841	Arginine vasotocin stimulates glucocorticoid secretion in male rats
	i	Instructions to contributors
	v	Editorial policy
	vi	Announcement
	vii	Forthcoming papers

VOL. 7 1983

AUTHOR INDEX

Adamec, R. E. 505
Addington, D. 529
Aizenstein, M. L. 187
Albala, A. A. 563
Annable, L. 669
Arato, M. 715
Aravagiri, M. 709
Arora, R. C. 39
Aschauer, H. 335

Baker, G. B. 747, 779, 783, 809, 813
Ballenger, J. C. 263
Banki, C. M. 715
Barone, D. 729
Batth, S. 719
Bautz, G. 629
Behrnetz, S. 367
Bell, J. 273
Belmaker, R. H. 287
Bendek, G. 203
Bender, A. S. 681
Bernardi, M. M. 187
Bigelow, L. B. 83
Bird, E. D. 725
Bland, B. H. 821
Bloom, F. E. 217
Boulton, A. A. 529, 611, 801
Bowen, R. C. 605, 611
Bozarth, M. A. 569
Broadbent, J. 801
Broekkamp, C. L. 585
Brown, G. M. 545, 557, 827, 841
Brown, P. J. 545
Bush, D. F. 367

Calverley, D. G. 783
Cannizzaro, G. 195
Carroll, B. J. 563
Cassone, M. C. 57
Chermat, R. 183
Chiu, P. 739
Chiu, S. 739
Chouinard, G. 669
Claghorn, J. 367
Cleghorn, J. M. 545
Colburn, W. A. 629
Cooper, S. J. 495, 787, 835
Coscina, D. V. 463
Coutts, R. T. 747, 779, 809, 813
Cowper, M. J. 703
Cutler, N. R. 83

Dakshinamurti, K. 743
Danielson, T. J. 747
Davis, B. A. 529, 611
Davis, J. M. 365
Delucia, R. 187
Dent, R. R. M. 525
Dewhurst, W. G. 783
Dick, E. 287
Dourish, C. T. 3, 487, 787
Dua, A. K. 647
Dubé, S. 89
Dudley, J. 791
Dulos, R. A. 709
Dyck, L. E. 797

Edmeads, J. 413
Ehlers, C. L. 217
Eison, A. S. 663
Eison, M. S. 663
Etienne, P. 537, 725, 765
Eugenio, H. 537
Evered, M. D. 469

Fessler, R. G. 39
Fibiger, H. C. 585
Flugy, A. 195
Fontaine, R. 669
Forney, E. 73
Fundaro, A. 57

Garcia-Sevilla, J. A. 241
Garcin, F. 1
Gauthier, S. 725
Geddes, J. 703
Gelfand, R. 719
Gershon, S. 227, 273, 367
Gillin, J. C. 297, 351
Globus, M. 211
Godse, D. D. 751
Gold, P. W. 263
Goldstein, B. J. 367
Gray, R. 719
Greenshaw, A. J. 801
Grof, E. 557
Grof, P. 557, 715, 831
Grota, L. 827
Gurnsey, T. S. 703
Guyda, H. 537

Haltia, M. 725

VOL.
7
1983

Hartley, L. R. 29
Haskett, R. F. 563
Hawes, E. M. 709, 791
Hedley, L. R. 47
Hertz, E. 691, 697
Hertz, L. 675, 681, 687, 691, 697
Hollingsworth, P. J. 241
Horst, W. D. 629
Hrdina, P. D. 457, 733
Huitfeldt, B. 367

Indik, J. H. 217

Jack, M. L. 629
Janowsky, D. S. 297
Jeste, D. V. 83
Jimerson, D. C. 249
Johnston, D. G. 617
Jones, D. 229, 273

Kafka, M. S. 249
Kaplan, R. D. 545
Keegan, D. L. 791
Kelwala, S. 229, 273
Klein, E. 287
Kleinman, J. E. 83
Klemm, W. R. 73
Koinig, G. 335
Koob, G. F. 217
Kreema, R. 773
Kulik, A. V. 223

LaBella, F. S. 647
Labonte, A. 669
Lake, C. R. 249
Lal, S. 537, 725, 765
Langer, G. 335
Lapierre, Y. D. 153, 641, 719, 733, 805
Legatt, D. F. 779
Lerer, B. 287, 309
Lewis, R. A. 651
Lewy, A. J. 551
Li, P. P. 751
Lizondo, E. 537
Locock, A. R. 809

MacIver, M. B. 821
Martin, I. L. 421, 433
McKay, G. 703
McKenzie, G. M. 761
McKenzie, S. G. 623
McKim, H. R. 783
McQuade, P. S. 755, 765
Melamed, E. 211
Meltzer, H. Y. 39
Micetich, R. G. 747, 809
Miczek, K. A. 519
Midha, K. K. 791
Mishra, R. K. 437, 729, 739, 769
Mitton, J. 545
Molinengo, L. 57
Murphy, D. L. 249

Nair, N. P. V. 537, 725, 765
Napier, T. C. 175
Nazarali, A. J. 813
Neff, G. L. 651
Newman, M. 287
Newton, R. E. 663
Niles, L. P. 841

O'Brien, R. A. 629
Oyewumi, L. K. 719, 733, 805

Paetau, A. 725
Palmour, R. M. 513
Palo, J. 725
Pasutto, F. M. 813
Paulose, C. S. 743
Pert, C. B. 451
Peterson, S. L. 175
Philips, S. R. 817
Phillips, A. G. 585
Pinsky, C. 647
Pirch, J. H. 175
Poiletman, R. M. 165
Post, R. M. 263
Powell, D. A. 101
Provenzano, P. M. 195
Puech, A. J. 183

Quirion, R. 451

Radouco-Thomas, C. 1
Ramwani, J. 769
Rastogi, R. B. 153
Rastogi, S. K. 153
Rauw, G. 791
Rauw, G. A. 709
Resch, F. 335
Riblet, L. A. 663
Richardson, J. S. 675, 681
Rigdon, G. C. 175
Rihmer, Z. 715
Risch, S. C. 297
Robertson, H. A. 637
Robitaille, Y. 725
Rogol, A. 83
Rotstein, E. 729, 831
Roth, S. H. 821
Rotman, A. 135
Rubinow, D. R. 263

Saunders, W. S. 477
Scavone, C. 187
Schönbeck, G. 335
Seggie, J. 773, 827
Sethi, B. B. 89
Shah, A. B. 101, 165
Shah, N. S. 101, 165
Sheehan, D. V. 599
Shimada, M. 63
Siever, L. J. 249
Singal, D. P. 729
Singhal, R. L. 153
Simon, P. 183
Sitaram, N. 227, 229, 273, 309
Smith, C. B. 241
Sourkes, T. L. 389
Spirit, N. M. 629
Stark–Adamec, C. I. 505
Sternberger, N. H. 427
Stevenson, J. 273
Stewart, J. 591
Stonkus, M. D. 709
Suzuki, T. 63

Targum, S. 249
Taylor, D. P. 663
Temple, Jr., D. L. 663
Thavundayil, J. 537
Thornhill, J. A. 477
Triezenberg, H. J. 651
Turkish, S. 835

Uesugi, J. 63
Uhde, T. W. 249, 263

Vogel, G. W. 343
Vonvoigtlander, P. F. 651

Wallach, M. B. 47
Walz, W. 697
Wan, Y. P. 739
Warenycia, M. W. 761
Warsh, J. J. 751
Weinberger, D. R. 83
Werner, L. 831
Werstiuk, E. 827
Werstiuk, E. S. 831
Wilbur, R. 223
Williams, M. 443
Wise, R. A. 569
Wong, Y. 739
Woods, J. 577
Wood, P. L. 537, 657, 725, 755, 765
Wormith, J. S. 529
Wyatt, R. J. 83

Yanaura, S. 63
Yoshii, T. 63
Yu, A. C. H. 691
Yu, P. H. 529, 611, 687

Zalcman, S. 83
Zanko, M. 629
Zis, A. P. 241, 563

OL.
7
983

SUBJECT INDEX

ABC syndrome 153
Abnormal involuntary movements 719–23
  rating 721, 722
Addiction 569–73
Adenosine
  anomalies 447, 448
  CNS function, therapeutic aspects 447
  CNS receptors 443–8
  neuromodulation 444
  physiological effects 443
  radioligand binding 446
Adenylate cyclase
  demeclocycline effects 292, 293
  lithium effects 288–90
  lithium inhibition specificity 290, 291
Adenylyl cyclase-binding sites and antidepressants 675–9
Adrenal gland
  chlordiazepoxide effects 773–6
  enzyme regulation 395
  neural pathways 396–9
  preganglionic sympathetic innervation 397
  response time 396–8
  stress role 389–91
Adrenal medulla
  catecholamines and stress 404
    spinal cord section 404, 405
  changes in stress 403, 404
6-Adrenergic binding
  agonist and antagonist effects 684
  glial cells 684
Adrenergic–cholinergic balance and affective disorder treatment 297–304
Adult onset disease 514
Adverse reactions
  amitriptyline 377–9
  apomorphine 86
  buspirone 666
  chlordiazepoxide 666
  demeclocycline 293
  diazepam 666
  L-DOPA 211
  extrapyramidal 223–5
  haloperidol 153, 154
  mianserin 736
  performance 29–35
  piribedil 18, 19
  propranolol 95
Affective disorders
  neuroendocrine strategies 557–61
  presynaptic markers 230–2
Aggression
  alcohol 521, 522, 527
  amphetamine effects 522
  androgens 525
  animal models 520
  drug effects 519–23
  endocrine correlation 525–7
  lateral hypothalamus 506
  limbic control in cat 505–10
  and renin 527
  sensory motor control 507
Aggressive behaviour
  biochemical correlation 529–34
  genetic models 513–16
  multifactorial inheritance 515
  Varimax Rotated Factor Matrix 531
Agoraphobia
  assessment 617–21
  Behavioural Approach Test 619, 620
  research methods 617
  syndrome 611
  trace amine metabolism 611–15
Akathisia, neuroleptic-induced; propranolol use 223–5
Alcohol effects on aggression 521, 522
Alcoholism and benzodiazepine use 645
Alprazolam in panic disorders 670, 671
Alzheimer's disease 726
Amines, MAO inhibitors and brain localization 783–6
γ-Aminobutyric acid *see also* GABA, receptor
  drinking 497, 498
  feeding 463–6, 497, 498
  phenylethylamine-induced seizures 790
Amitriptyline
  adverse reactions 377–9
  patient criteria 382
  zimelidine comparison in depression 367–82
AMP, dibutyryl 688, 697
Amphetamine
  and aggression 522
  N-alkylated analogues 813–15
    brain concentration 815
  fencamfamine comparison in behaviour 189–91
  and locomotor activity after electroconvulsive therapy 219, 220
  monofluorinated, responses 747–50
Anaesthetics, design of specific 649
Analgesics
  assay 648, 651
  end-points, drugs affecting 654
  new concepts 647–9
    biogenic amines 651–5
  self-administration animals and humans 579, 580
Androgens and aggression 525, 526
Angel Dust *see* phencyclidine
Angiotensin II

circulating hormone 470
neuropeptide 470, 471
Animal models
aggression 520, 521
anxiolytics 664
and clinical testing 227, 228
epilepsy 637
Animal studies, drug taking 577–82
Anorexia specificity 466
Anorexiants 813
Antibody *see* monoclonal
Antidepressants
α_1-adrenergic upregulation 284
criteria for mechanism 344
mechanisms 365
MHPG levels 235
monoamine receptor changes 249–58
platelet α_2-adrenoreceptors 241–6
REM sleep deprivation 343–8
response prediction 229–36, 335–41
sleep 352–9
Antidepression response, iris pharmacology 273–84
Antidipsogenic effects 195
Anxiety
diazepam and buspirone 666
rebound 669, 670
Anxiety disorders
anxioselective 663–7
benzodiazepine use 643–5
classification 600
diagnostic problems 599, 600
differential diagnosis 605–8
exogenous, subtypes 601
organic syndromes 605–7
treatment 602, 603
Apomorphine
clinical response in schizophrenia 86
induced stereotypy and nisoldipine 168, 169
locomotor activity and electroconvulsive shock 218, 219
response and schizophrenia subtyping 83–7
Apomorphine-induced gnawing
cholinomimetic effects 51, 53
clozapine potentiation 49
dose effect 48, 49
and climbing 48
drugs interacting 50, 52
mice 47–54
propranolol effects 53, 54
Arginine vasotocin
endocrine effects 844
glucocorticoid secretion 841–4
Astrocytes
antidepressant effects 675–9
barbiturate effects in metabolism 691–5
benzodiazepine β-adrenergic binding 681–5
dihydroalprenolol retention, drugs affecting 677, 678
lithium–potassium interaction 697–701
ATPase, Na^+-K^+
assay 698
lithium effects in neuron and astrocytes 700
Autism, platelet 5-HT uptake 138, 139

Barbiturates, astrocyte metabolism 691–5
Behavioural Approach Test 619, 620
Benzodiazepines *see also* GABA-benzodiazepine receptor
absorption 642
antagonists 637
anxiety states 644
astrocyte binding 681–5
clinical equivalence 641–5
cortical binding 632, 633
distribution and steady state 642, 643
effect timing 626, 627
feeding and drinking 495, 496
half-life 624, 625
lipid solubility 625, 626
mechanism of action 422, 423
pharmacodynamics 623–7
potent, indications 670–2
psychometric response 625
receptor binding model 629–34
selection criteria 643, 644
structure and activity 423, 424
withdrawal 421, 422
Blindness, light and melatonin production 552, 553
Body temperature and fluorinated amphetamines 748, 749
Bombesin and water intake 473
Brain, methylphenidate localization 102–4
Brief Psychiatric Rating Scale (BPRS)
modified and propranolol in schizophrenia 92, 93
Bromazepam 671, 672
Bromocriptine
brain DOPAC 212, 213
in Parkinson's disease 211
striatal dopamine 213
Buspirone 663–7
animal models 664
CNS depressant potentiation 665
features 663, 664
mechanism of action 664
muscle relaxant 665

Calcium entry blocker *see also* nisoldipine
stereotypy in rats 165–71
Carbamazepine
biochemical effects 263–8
clinical uses 263, 264
dopaminergic effects 265
GABA effects 265
endocrine effects 267
peptide effects 268
receptor effects 265–7
Cell culture *see also* astrocytes
astroglial 687–90
drugs affecting β-ligand retention 679
long-term glial and monoamine oxidases 687–90
neurone 681–5
Ceruletide

growth hormone secretion 540
prolactin secretion
CGS-8216 637
Chlordiazepoxide
behaviour and adrenal effects 773–6
time 774
corticosterone effects 775
p-Chlorophenylalanine and analgesia effects 652
brain thymidine accumulation and transport 208
Chlorpromazine
HPLC–EC analysis 704, 705
noise in detection task 32
plasma levels 705
Cholecystokinin and peptides
dopaminergic function in man 537–42
growth hormone secretion 538, 539
mesolimbic and dopamine 441
prolactin secretion 540, 541
Choline acetyltransferase, cortical in dementias 726
Cholinergic mechanisms, lithium effects 301, 302
Cholinesterase inhibitors, effects 299
Cholinomimetics
anticholinergic 200
challenge, diagnostic use 303
clinical applications 301
effects on man 298
effects on mania 299, 301
potentiation 301
Circadian rhythms, light and melatonin effects 531–4
Clinical Global Impression, zimelidine and amitriptyline in depression 376
Clonazepam in mania 671
Clonidine, receptor response in depression 252–5
Clozapine, striatal dopamine metabolites 767
Cocaine, spiroperidol effect on self-administration 588
Comprehensive Psychopathological Rating Scale (CPRS) 89
and propranolol in schizophrenia 92–5
Computed tomography (CT) in schizophrenia 84, 85
Conditioned place preference, haloperidol and 6-hydroxydopamine effects 587
Cortex
neuron firing rates 177
neuron responses to trazodone 175–80
Corticosterone
arginine vasotocin effects 843
plasma and chlordiazepoxide 775
Cortisol, morphine effects on plasma 565
depression 566
CRL–40028
α-adrenergic stimulation 183
composition 183
α-methylparatyrosine interaction 185
prazosin-induced hypomotility 184
prazosin-induced hypothermia 184, 185
prazosin interaction 185

Defence, limbic modulation 510
Defensive cats 509
Demeclocycline
and amphetamine-induced hyperactivity 293
clinical uses 293, 294
noradrenaline-sensitive adenylate cyclase 292, 293
Dependence
benzodiazepines 645
morphine in food 63–70
Depression
amphetamine-growth hormone test 715, 716
and antidepressant binding 457–61
benzodiazepines 645
bipolar 558
catecholamine role 564
cortisol role 565, 566
mianserin effects and plasma levels 733–7
monoamine receptors 249–58
morphine effects on cortisol 565, 566
phase-advanced circadian rhythm 554
platelet 5-HT uptake 137, 138
platelet receptor binding 242–6
receptor sensitivities 251, 252, 256, 257
clonidine 252–5
fenfluramine 255, 256
sleep therapies 343–8, 351–61
temperature 357
TSH response to TRH 717
Desipramine
cortical neuron responses 175–80
firing rates 178
high affinity brain binding 460
localization 460, 461
Dexamethasone suppression escape and opioid mechanism 563–7
Dexamphetamine immobilization and striatal neurons 761–4
Diazepam
cortex binding parameters 632, 633
phenylethylamine-induced seizures 789
Dihydroxyphenylethyleneglycol
fate in mouse brain 751–4
inhibitor effects 753
DOPAC (dihydroxyphenylacetic acid)
striatal, L-DOPA and bromocriptine effects 212, 214
Dopamine
agonists and drinking 488–90
antagonists and drinking 490, 491
central, MAO inhibitor effects 783–6
metabolism and phenylethylamine 755–8
pathway lesions and thirst 488
release and potassium chloride 817–20
caudate putamen 819
nucleus accumbens 819
striatal and behaviour 104
striatal and phenylethylamine 799
supersensitivity after haloperidol 161
Dopamine agonist 3–21 *see also* piribedil
Dopamine synaptic activity 15
Drinking, dehydration stimulation route 471
Drinking behaviour
benzodiazepine effects 495–9

VOL. 7 1983

dopamine agonist role 488–90
dopamine antagonist role 490, 491
dopaminergic involvement 487–91
Drugs
action scheme 624
apomorphine-induced behaviour 50, 52
performance 29–35
platelet evaluation 144
reinforcement 57–62
substrate study 585–9
Drug-taking
animal and human 577–82
assessment of study 581, 582
conditioning of effects 593, 594
reinstatement
central application 593
priming injections 592, 593
relapse 591–5
routes 581
DSM–III and anxiety disorders 643

Electroconvulsive shock (ECS, ECT)
acetylcholine receptors 311, 322–4
behavioural effects
amphetamine 219, 220
apomorphine 218, 219
mechanisms 219
clinical strategies and human 312–14
cortisol 318, 320
dopamine receptors 310, 311
dopamine system 217
growth hormone 317, 318, 320
5-HT receptors 311,314,315
mechanisms 309–25
MHPG effects 318
noradrenergic receptor effects 311, 316–22
opiate receptors 323, 325
psychophysiological effects 319–22
Electron capture gas chromatography 779
Enzymes
adrenal regulation 395
hormonal induction 391–4
stress target 391
transneural induction 394–6
Epilepsy
benzodiazepine antagonists 638
temporal lobe, benzodiazepine treatment 637–9
Erythrocyte, lithium uptake and haloperidol 831–3
Ethanolamine-*O*-sulphate
acute overeating 464, 465
chronic overeating 465, 466
Ethological analysis, drug action on aggression 519–23
Extrapyramidal syndrome, neuroleptics 721

Fear questionnaire 618
Feeding
benzodiazepine role 495–9
chronic morphine 482, 483
stimulation and morphine sulphate 477–84
Fencamfamine
behavioural effects 189–91
brain DOPAC 190
brain homovanillic acid 190
dose in rats 188
formula 187
neurochemical effects 189, 192
Fenfluramine, receptor response and depression 255, 256
Fenproporex 813
structure 814
FLA–63
brain thymidine accumulation 205
brain thymidine metabolism 207
brain thymidine transport 206
dopamine and norepinephrine brain levels 206
Fluphenazine
determination methods 794
plasma levels and clinical response 791–5
intramuscular 792, 793

GABA transaminase inhibition and overeating 463–6
Gate control theory, pain 415, 416
Gerstmann Straussler syndrome 726
Glucocorticoids secretion and arginine vasotocin 841–4
Gnawing, apomorphine-induced 47–54
Growth hormone
amphetamine response in depression 715, 716
apomorphine response in schizophrenia relapse 546
CCK-peptide effects 538, 539
diet effects and lithium 828, 829
electroconvulsive therapy 317–19

Haloperidol
apomorphine-induced behaviour 155, 156
behavioural testing 154
brain 5-HIAA and withdrawal 157, 158
brain 5-HT and withdrawal 157, 159
dopamine and norepinephrine metabolism 155, 157, 158
dopamine supersensitivity 161
GABA and withdrawal 157, 160
glutamic acid decarboxylase and withdrawal 157, 160
-lithium treatment 831–4
lithium uptake by erythrocytes 833
treatment and withdrawal 153–62
tyrosine hydroxylase and withdrawal 157
Hamilton ratings
amitriptyline and zimelidine 373–5
mianserin and symptom clusters 735
therapeutic outcome 375
High performance liquid chromatography (HPLC)
-electrochemical detection 704
phenothiazine analysis 703–7
Homovanillic acid, antidepressant response 235

Horner's syndrome, induced; pupil response 275, 276
6-Hydroxydopamine, rat lesions and unit activity 77, 78
Hydroxyphenylacetic acid and aggression 531
5-Hydroxytryptophan (5-HT)
  glial cell MAO response 688, 689
  decreased in pyridoxine deficiency 743–5
  platelet and synaptosome uptake 136
  platelet uptake
    drugs affecting 144
    lithium carbonate 39–43
    mental illness 137–9
  striatal and phenylethylamine 799
  uptake measurement 40
Hyperactive child, vigilance and drugs 31
Hyperactivity, amphetamine-induced and demeclocycline 292
Hyperthyroidism in anxiety 606
Hyperventilation syndrome and anxiety 606, 607
Hypochondriasis 601
Hypoglycaemia in anxiety 605, 606

Imipramine
  depression improvement 346
  high-affinity brain binding 458
    localization 459
    pharmacological profile 458, 459
    significance 459, 460
  platelet binding in mental illness 139, 140
Insomnia management and benzodiazepines 644, 645
Intracranial self-stimulation 585, 586
Intravenous self-administration 588, 589
Iris *see also* pupil
  pharmacology 273–84
  physiology 275
  receptor studies 274, 275

Kappa agonists 657–61 *see also* receptors, opioid 657–61
Ketanserin and analgesia effects 653
Kindling 637

Lesch-Nyhan disease, features 515, 516
Light
  biological effects 551, 552
  effects in blindness 552, 553
  manic-depressive sensitivity 554
  phase response curve 553
Lithium
  adenylate cyclase effects 288, 289
    demeclocycline 292, 293
    noradrenaline sensitive 289, 290
    specificity of inhibition 290, 291
  bipolar depression 558
  carbonate
    5-HT uptake by rat platelets 39–43
    plasma and platelet levels 41
    treatment duration and plasma levels 41, 42
  cholinergic mechanisms 301, 302
  and haloperidol treatment 831–4
  hormonal diurnal effects 827–9
  internal loading 699
  potassium interaction 697–701
  potassium uptake 698, 699
  prolactin response to hypoglycaemia 559–61
  veratridine-treated neurons 699, 700
Locomotor activity and electroconvulsive shock 217–21
  amphetamine effects 220
  apomorphine effects 218
Lorazepam, cortex binding parameters 632, 633
Lymphocyte, spiroperidol binding in schizophrenia 729–32

Mania, cholinomimetic effects 299
Manic-depression, circadian rhythms 554
Melatonin
  blindness 552, 553
  circadian marker 552
  diet effects and lithium 828, 829
Memory, drug effects 34, 35
3-Methoxy-4-hydroxyphenylethylene glycol (MHPG)
  affective disorder marker 230, 232
  excretion and antidepressant response 233, 234
  fate and inhibitors 753
  high and low excretors 233, 234
Methylphenidate
  intraventricular 102, 103
  medulla oblongata 103
  rat brain localization 101–5
Mianserin
  clinical assessment 734
  Hamilton ratings 735
  plasma levels 736
    depression 733–7
Midazolam, cortex binding parameters 632, 633
Mitral valve prolapse syndrome, anxiety 607
Monoamine metabolites and antidepressant response prediction 229
Monamine oxidase
  A and B in long-term glial cell culture 687–90
  activity analysis 688
  agoraphobia 612–15
  inhibitor
    receptor changes 278–84
    p-tyramine levels 779–81
  platelet activity in mental illness 141, 142
  platelet and violent offenders 532
Monoclonal antibodies
  anti-neuronal 428
  assay 428
  electrophoresis 430
  peripheral organ reaction 430
  tissue staining, antineurofilament 429
Morphine
  behaviour and withdrawal 66
  blood glucose and insulin 483, 484
  body weight 65–7

VOL. 7 1983

catecholamine role 73–80
circadian feeding responses 480
cortisol secretion in depression 565, 566
dependence and tolerance after feeding 63–70
feeding stimulation 477–84
noradrenergic brain effect 79, 80
post-injection feeding 480–2

Naloxone
antidipsogenic 195–202
dose 196
effects on morphine withdrawal 66, 67
quarternary 838
saline drinking 837
water intake in acute and chronic deprivation 197, 198, 835–8
bar pressing 199, 200
Neuroendocrine tests for endogenous depression 715–18
Neuroleptics
dopamine metabolites 766
involuntary movements 719–23
nigrostriatal responses 765–7
receptor binding profiles 766
Neurotensin and water intake 472
Nigrostriatal tract
neuroleptic types and responses 765–7
in stress 401–3
Nisoldipine
behavioural effects 167
dose 166
pretreatment and stereotypy 168
stereotypy in rats 165–71
apomorphine-induced 170
phencyclidine-induced 167, 169
Noradrenaline, central and MAO inhibitor effects 783–7

Opiates
feeding and drinking 498, 499
pain neurotransmission 416
and water intake 473
Opiate reinforcement
dopaminergic role 571, 572
hypothalamic, self-stimulation 586
neural substrates 569–73
physical dependence 572
receptor localization 570, 571
Opioides
agonists structures 658, 659
antagonist structures 658, 659
CNS receptors 657
dexamethasone suppression escape 563–7
feeding and drinking 498, 499
kappa agonists 658–60
Ornithine decarboxylase
adrenomedullary regulation 400, 401
brain lesion and activity 394
hormonal induction 392
hypophysectomy and ACTH effects 393
Overeating, reversal and GABA transaminase inhibition 463–6

Pain
ascending pathways 415
gate control theory 415, 416
inhibitory systems 417
neurotransmitters 416
physiology 413–18
receptors 414, 415
therapy 418
Panic 601
agoraphobia 611–15, 617–21
attacks and trace amines 611–15
benzodiazepines 670, 671
fear comparison 605
Parkinson's disease
L-DOPA and bromocriptine 211
piribedil effects 18, 19
Partial complex seizures and anxiety 607
Pentobarbital
astrocyte oxygen uptake 692
biphasic action 823, 824
glutamate and astrocyte CO_2 production 693, 694
malate and astrocyte CO_2 production 693
synaptic sites 823, 824
synaptic transmission effects 821–4
Pentylene tetrazol seizures 788
Peptidase inhibitors in analgesia 647–9
Peptides
affecting water uptake 472
CNS binding sites 437
physiological role 473, 474
thirst 469–74
Performance, drug effects 29–35
Phaeochromocytoma and anxiety 605
Pharmacodynamics 624
benzodiazepines 623–7
Pharmacokinetics 624
benzodiazepines 623–7, 642, 643
Phencyclidine
Angel Dust abuse 451
drug competitive binding 453, 454
hydrochloride
induced stereotypy 167, 169
mechanism of action 170, 171
preincubation and olfactory bulb binding 452
receptor properties 451–4
structure–activity 452, 453
Phenelzine
brain amine localization 783–6
brain tyramine 780
striatal monoamine release 797–800
Phenothiazines
HPLC–EC detection 703–7
radioimmunoassays 709–14
detection limit 714
Phenylethanolamine
licking 803
water intake 801–4
β-Phenylethylamine

dopamine metabolism effects 755–8
glial cell MAO response 688, 689
-induced seizures 787–90
licking 803
striatal monoamine release 797–800
tyramine metabolism effects 755–8
water intake 801–4
Phenylmethylsulfonyl fluoride
β-endorphin potentiation 648
features 647
Phobia *see also* anxiety
Photoperiodism 554
Pick's disease 725–7
markers 726
Pimozide, brain thymidine DNA incorporation 209
Piribedil
aggression 9
behavioural effects 2–13
chemical structure 5
cholinergic activity 17
circling 7
clinical effects 19–20
dopamine receptors and apomorphine 16
dopaminergic action 13–16
feeding and drinking 10–12
locomotor activity 7, 8
noradrenergic activity 17
reward 10–13
serotonergic activity 17
stereotypy 4–7
and amphetamine 6
tyrosine hydroxylase 15
Platelets
aggregation in mental illness 141
binding studies in depression 242–6, 256, 257
drug evaluation 144, 145
5-HT uptake and mental illness 136–9
imipramine binding in mental illness 139, 140
monoamine oxidase 141, 142
release reaction 143
research 135–45
shape changes 142, 143
Potassium chloride and brain dopamine release 817–20
Prazosin effects in mice 183
Predation, rodent 508
Prolactin
arginine vasotocin effects 844
CCK peptide effects on secretion 540, 541
lithium effect 828, 829
response to hypoglycaemia in depression 559–61
lithium effect 860
Prolyl-leucyl-glycinamide
analogue displacement 741
binding assay 739
binding distribution 742
CNS receptors 437
D–1 and D–2 receptor interaction 440
haloperidol blockade 438
kinetic binding data 740, 741
locomotor activity and apomorphine 438
striatal membrane binding 740
Propranolol
essential tremor 225
mechanisms of action 90
neuroleptic-induced akathisia 223–5
response assessment 91
use in schizophrenia 89–97
schedule 91
Pupil
monoamine oxidase inhibitor responses 278–82
receptor sensitivity 284
role in medicine 275
sympathomimetic response 276
test system 277
Pupillography 278, 279
MAO inhibitor response 282
methodology 280
phenylephrine response 283
Pyridoxine-deficient rat
5-HT decrease effect 743–5
5-HT functional deficiency 744

Quaking mice, prazosin and CRL 40028 effects 185, 186

Radioimmunoassay, phenothiazines in plasma 709–14
Reaction time
alcohol 34
morphine feeding 68
tranquillizers 33, 34
Receptors, acetylcholine
electroconvulsive therapy 311, 322–4
Receptors, adenosine
characterization 445–7
mammalian CNS 443–8
release and uptake 445
subtypes 444, 445
Receptors, adrenergic and electroconvulsive therapy 311, 317
Receptors, α-adrenergic and agonist CRL 40028 183–6
Receptors, α_2-adrenergic, platelet
animal 242
clonidine binding in depression 244, 246
endogenous depression 242, 243, 256, 257
numbers in antidepressant therapy 241–6
yohimbine binding in depression 244–6
Receptors, β-adrenergic and electroconvulsive therapy 317
Receptors, benzodiazepine
anticonvulsant and sedative types 637–9
clinical correlations 633, 634
ex vivo binding parameters 631, 633
pharmacokinetic/pharmacodynamic binding model 629–34
equations 631
scheme 630
tetrahydro-β-carboline stereoisomers 809–12
Receptors, dopamine
apomorphine and piribedil effects 16
binding parameters 770–2

CCK 441
drug interaction model 14
electroconvulsive therapy 310, 311
inhibition 15
membrane preparation 769, 770
mesolimbic supersensitivity 439
nigrostriatal lesion 14
peptide modulation 437–41
solubilization method 769–72
criteria 772
procedure 770
Receptor, GABA-benzodiazepine 433–6
binding assays 433
equilibrium 434
Receptor, 5-HT and electroconvulsive therapy 311
animals 314, 315
humans 315, 316
Receptors, monoamine
affective disorders and antidepressants 249–58
clonidine response in depression 252–5
fenfluramine response in depression 255, 256
Receptors, opiate and electroconvulsive therapy 311, 323, 325
Receptors, opioid
CNS populations 657
κ agonist affinity 657–61
μ classification 659
types and affinities 660
Receptor, phencyclidine, rat brain 454
Reinforcement
fixed interval and fixed ratio, drug effects 57–62
schedules 59, 60
REM-sleep deprivation
antidepressant action 343–8
behaviour in animals 347
criteria 344, 345
depression assessment 345
discharge and imipramine in depression 346
drug effects in failure 347
Reserpine and analgesic effects 652
Ro15–1788 637
anticonvulsant 638, 639

S584, structure 5
Schaffer collateral fibers 822
Schizophrenia
apomorphine response and typing 83–7
growth hormone response variability 547, 548
hormone response instability 545–8
lymphocyte spiroperidol binding 729–32
piribedil effects 18–20
plasma fluphenazine and response 791–5
platelet 5-HT uptake 138
propranolol 89–97
Serotonin *see* 5-hydroxytryptamine (5-HT)
Skinner Box, water deprivation and naloxone 198–200
Sleep *see also* REM-sleep
therapies of depression 351–61
types 352
Sleep deprivation
biological rhythms 356
partial, effects 358, 359
prophylactic effects 357, 358
total, antidepressant effects 352–6
Sleep-wake cycle, phase advance and depression 359
Stereotypy
fencamfamine and amphetamine effects 189–91
nisoldipine effects 165–71
Stress
adrenal medulla 403–5
adrenal role 389–91
CNS pathways 389–406
enzymes 391–6
Striatum, neuron response to dexamphetamines 761–4
Substance P and pain 416
Suriclone
clinical assessments 806, 807
Synaptic transmission
enhancement 822
pentobarbital biphasic action 821–4

Tachykinins and water intake 473
Tardive dyskinesia
animal model 153–62
neuroleptics 722
Testosterone, arginine vasotocin effects 844
Tetrahydro-β-carbolines
benzodiazepine receptor 809–12
structure and stereoisomers 811
Thirst and neuropeptides 469–74
Thymidine
brain metabolism in rat pups 203–9
chromatography 204
Tolerance, morphine feeding 65
Trace amines
aggression 530
agoraphobia 611–15
Tranylcypromine
brain amine localization 783–6
brain tyramine 780
Trazodone
cortical neurone responses 175–81
firing rates 179
dose 176
TRH, TSH-response test 717
antidepressant action 335–41
Trifluoperazine
antisera sensitivity 713
immunogen cross reactivity 712
structure and immunogens 710, 711
tablet formulation 712
Trimeprazine
HPLC–EC estimation 706
plasma concentration and time 707
Tryptophan pyrrolase, stress induction 392
TSH-response to TRH
antidepressant therapy 339, 340

depression and paranoid hallucination 337, 338
neuroleptic response 341
Tyramine
chronic MAO inhibitors 779, 780
metabolism and β-phenylethylamine 755–8
m-Tyrosine analgesia and antagonists 655
Tyrosine hydroxylase
adrenal and spinal cord section 402
adrenomedullary up-regulation 399, 400
down-regulation 401

U–50488H analgesia 652, 653
Unit activity
brain areas 79
6-hydroxydopamine lesions in rats 77–9
morphine action assessment 73–82
morphine effect and noradrenergic areas 79, 80
sham operated rats 75–7

Vasopressin and water intake 472
Vigilence, drug effects 30–2
chlorpromazine 32
tranquillizers 31, 32
Violence, biochemical variables 531, 533

Water deprivation
acute and chronic effects 197–9
naloxone effects 195–202
and uptake with naloxone 835–8
Water intake
naloxone effects 835–8
phenylethanolamine 801–4
β-phenylethylamine 801–4
Withdrawal
benzodiazepines 421, 422
rebound anxiety 670
haloperidol effects 155, 156
morphine and naloxone in rats 64, 65
morphine treatment period 68, 69
signs 66, 69
Writhing test, analgesics and antagonists 654

Zimelidine
adverse reactions 377–9
dose 372
evaluation in depression 367–82
evaluation method 369
Hamilton ratings 373–5
interclinic differences 379
patient criteria 382
patient selection 368, 369, 372
Zucker rats, opioid peptides and feeding 477, 478

OL.
7
983

Progress in Neuro-Psychopharmacology & Biological Psychiatry
An International Research, Review and News Journal

EDITORIAL ADVISORY BOARD

V. N. BAGADIA, Bombay
A. BARBEAU, Montreal
J. BRUINVELS, Rotterdam
J. R. BUENO, Rio de Janeiro
W. E. BUNNEY, Bethesda
G. D. BURROWS, Melbourne
M. CAMPBELL, New York
G. B. CASSANO, Pisa
T. N. CHASE, Bethesda
J. COLLARD, Liége
A. J. COPPEN, Epsom
J. T. COYLE, Baltimore
P. CUATRECASAS, Res. Triangle Park
E. CUENCA, Cadiz
H. C. B. DENBER, Louisville
W. L. DEWEY, Richmond
E. F. DOMINO, Ann Arbor
J. ENGEL, Goteborg
S. GARATTINI, Milano
F. GARCIN, Quebec
J. GAUTIER, Quebec
L. GESSA, Cagliari
C. GIURGEA, Brussels
S. C. GOLDBERG, Rockville
A. GOLDSTEIN, Palo Alto
F. K. GOODWIN, Bethesda
L. F. GRAM, Copenhagen
J. P. GREEN, New York
R. N. GROVE, Quebec
W. E. HAEFELY, Basle
H. HALBACH, Wildenwart
L. HARRIS, Richmond
R. HEACOCK, Ottawa
H. HEIMANN, Tubingen
P. D. HRDINA, Ottawa
T. HOKFELT, Stockholm
P. HUGHES, Geneva
M. R. ISSIDORIDES, Athens
T. M. ITIL, New York
H. ITOH, Tokyo
J. JACOB, Paris
W. JANKE, Dusseldorf
L. F. JARVIK, Los Angeles
L. JULOU, Paris
K. KALANT, Toronto
S. KANOWSKI, Berlin
N. KHAZAN, Baltimore
K. F. KILLAM, Davis
N. S. KLINE, Orangeburg
C. KORNETSKY, Boston
H. W. KOSTERLITZ, Aberdeen
F. LABRIE, Quebec
M. H. LADER, London
H. LAL, Kingston, RI
V. G. LONGO, Roma
P. LUNDBORG, Goteborg
L. MANARA, Milano
P. MANDEL, Strasbourg
W. R. MARTIN, Lexington
M. O. MAYKUT, Ottawa
N. K. MELLO, Belmont, MA
H. Y. MELTZER, Chicago
J. MENDELS, Philidelphia
J. MENDLEWICZ, Brussels
P. L. MORSELLI, Paris
R. D. MYERS, West Lafayette
R. A. NICOLL, San Francisco
M. O. OLATAWURA, Ibadan
A. OLIVERIO, Roma
R. PAOLETTI, Milano
C. B. PERT, Bethesda
P. PICHOT, Paris
A. PLETSCHER, Basle
S. N. PRADHAN, Washington
A. J. PRANGE, Chapel Hill
E. RICHELSON, Rochester
K. RICKELS, Philadelphia
L. N. ROBINS, St Louis
I. ROOTMAN, Ottawa
R. H. ROTH, New Haven
B. SALETU, Vienna
N. SARTORIUS, Geneva
G. J. SARWER-FONER, Ottawa
M. SCHOU, Risskov
C. R. SCHUSTER, Chicago
W. J. SHOEMAKER, San Diego
B. SHOPSIN, New York
L. SHUSTER, Boston
E. J. SIMON, New York
P. SIMON, Paris
P. SINGH, Quebec
T. L. SOURKES, Montreal
C. N. STEFANIS, Athens
R. STRETCH, Ottawa
F. SULSER, Nashville
S. SZARA, Rockville
L. TERENIUS, Uppsala
T. THOMPSON, Minneapolis
M. TRABUCCHI, Milano
L. TRENHOLM, Ottawa
K. UNNA, Chicago
L. VALZELLI, Milano
W. L. VEALE, Calgary
A. VILLENEUVE, Quebec
O. VINAR, Prague
E. L. WAY, San Francisco
J. S. WERRY, Auckland
D. WHEATLEY, Twickenham
J. R. WITTENBORN, New Brunswick, NJ
J. WOODS, Ann Arbor

OL.
7
983

Prog. Neuro-Psychopharmacol & Biol. Psychiat. 1983, Vol. 7, pp. 1
Printed in Great Britain. All rights reserved.

0278-5846/83/010001-01$03.00/0
Copyright © 1983 Pergamon Press Ltd.

EDITORIAL NOTE

The Editors and the Publisher are pleased to inform the readers that our Journal will publish a periodical of the World Health Organization (WHO) namely:

Biological Approaches to Mental Health
A WHO Newsletter

This publication will start with Vol. 7, Issue 1 (this Issue). It will be included in Section 4 "News and Intercommunications" and will consist in an English and a French version. The editorial work is under the supervision of Dr. P.V. Morozov, WHO Senior Officer, Dr. Alice Leeds from NIMH Rockville, Dr. Françoise Garcin and Dr. C. Radouco-Thomas from Laval University Medical School, Quebec, Canada.

For several years, our Journal has been in close collaboration with the WHO Division of Mental Health. Two of the main officers of this division, Dr. N. Sartorius, Director, and P.V. Morozov, Senior Medical Officer, actively cooperate with the Journal as members of the Editorial Board. Moreover, the Journal already published (2) the Symposium on "Perspectives in Psychopharmacotherapy" held in Milan under the auspices of WHO.

Detailed information on this WHO Newsletter are given in Section 4 of this Issue (see Aims and Editorial Policy). We would like to underline here that one of the main purposes of this WHO Newsletter is to facilitate and promote exchange of information among scientists and mental health workers from different parts of the world. Such an exchange as well as collaboration between institutes and individuals at the international level are among the essential aims of the World Health Organization because it is the belief of WHO that progress is only possible through joint work and collaboration involving people from all over the world; north and south, east and west (1). The "WHO Newsletter" dedicated to biological approaches to mental health aspires to become an important tool in fulfilling this aim.

We hope that this new periodical will complement successfully the aims and scope of our Journal for the general benefit of the members of neuro-psychopharmacological and biological psychiatry communities.

Françoise Garcin Corneille Radouco-Thomas

References

1. SARTORIUS, N., Opening address (1981) 3rd World Congress of Biological Psychiatry, July. (Personal communication).

2. VARTANIAN, F.E., GARCIN, F., RADOUCO-THOMAS, C. and GORINI, S. (1979) Perspectives in Psychopharmacotherapy. Prog. Neuro-Psychopharmacol. 3: 1.

VC
7
19

CRITICAL REVIEWS AND THEORETICAL ARTICLES

OL.
7
983